OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1577-1577
Open Access | Times Cited: 15
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1577-1577
Open Access | Times Cited: 15
Showing 15 citing articles:
Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study
Ming Hong Choi, Eric Yuk Fai Wan, Ian Chi Kei Wong, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 11, pp. 1213-1224
Closed Access | Times Cited: 9
Ming Hong Choi, Eric Yuk Fai Wan, Ian Chi Kei Wong, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 11, pp. 1213-1224
Closed Access | Times Cited: 9
Impact of the main pharmacological option for COVID-19 disease progression in hospitalized patients in northern Italy: a single-center retrospective study
Cesare Bolla, Serena Penpa, Eleonora Sarchi, et al.
Deleted Journal (2025) Vol. 64, Iss. 1
Closed Access
Cesare Bolla, Serena Penpa, Eleonora Sarchi, et al.
Deleted Journal (2025) Vol. 64, Iss. 1
Closed Access
Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
Anna Gidari, Samuele Sabbatini, Sabrina Bastianelli, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 354-354
Open Access | Times Cited: 3
Anna Gidari, Samuele Sabbatini, Sabrina Bastianelli, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 354-354
Open Access | Times Cited: 3
A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication
Christopher Moon, Eleanor Porges, Adam P. Roberts, et al.
Antiviral Research (2024) Vol. 225, pp. 105859-105859
Open Access | Times Cited: 3
Christopher Moon, Eleanor Porges, Adam P. Roberts, et al.
Antiviral Research (2024) Vol. 225, pp. 105859-105859
Open Access | Times Cited: 3
Unlocking the potential of remdesivir: innovative approaches to drug delivery
Maie S. Taha, Ahsan R. Akram, Ghada A. Abdelbary
Drug Delivery and Translational Research (2025)
Open Access
Maie S. Taha, Ahsan R. Akram, Ghada A. Abdelbary
Drug Delivery and Translational Research (2025)
Open Access
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
(2024)
Open Access | Times Cited: 2
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
(2024)
Open Access | Times Cited: 2
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 168-168
Open Access | Times Cited: 2
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 168-168
Open Access | Times Cited: 2
Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients
Chiara Sepulcri, Claudia Bartalucci, Małgorzata Mikulska
Current Opinion in Infectious Diseases (2024) Vol. 37, Iss. 6, pp. 506-517
Closed Access | Times Cited: 2
Chiara Sepulcri, Claudia Bartalucci, Małgorzata Mikulska
Current Opinion in Infectious Diseases (2024) Vol. 37, Iss. 6, pp. 506-517
Closed Access | Times Cited: 2
Repurposing Drugs and Synergistic Combinations as Potential Therapies for Inhibiting SARS-CoV-2 and Coronavirus Replication
Richard Boulon, Clément Mazeaud, Majid D. Farahani, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 4043-4055
Open Access | Times Cited: 1
Richard Boulon, Clément Mazeaud, Majid D. Farahani, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 4043-4055
Open Access | Times Cited: 1
Protective Effect of Indole-3-Aldehyde in Murine COVID-19-Associated Pulmonary Aspergillosis
Marilena Pariano, Anna Gidari, Claudia Stincardini, et al.
Journal of Fungi (2024) Vol. 10, Iss. 7, pp. 510-510
Open Access
Marilena Pariano, Anna Gidari, Claudia Stincardini, et al.
Journal of Fungi (2024) Vol. 10, Iss. 7, pp. 510-510
Open Access
Efficient in vitro assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains
Maximillian Woodall, Samuel Ellis, Shengyuan Zhang, et al.
Antimicrobial Agents and Chemotherapy (2024)
Open Access
Maximillian Woodall, Samuel Ellis, Shengyuan Zhang, et al.
Antimicrobial Agents and Chemotherapy (2024)
Open Access
Impact of the Main Pharmacological Option and Risk Factors for COVID-19 Disease Progression in Hospitalized Patients in Northern Italy: A Single-Center Retrospective Study
Cesare Bolla, Serena Penpa, Eleonora Sarchi, et al.
(2023)
Open Access | Times Cited: 1
Cesare Bolla, Serena Penpa, Eleonora Sarchi, et al.
(2023)
Open Access | Times Cited: 1
Remdesivir and Nirmatrelvir Show Consistent Synergistic Efficacy Across Ancestral and Newly Emerged Sars-Cov-2 Clinical Isolates
Maximillian Woodall, Samuel Ellis, Shengyuan Zhang, et al.
(2024)
Closed Access
Maximillian Woodall, Samuel Ellis, Shengyuan Zhang, et al.
(2024)
Closed Access
Special Issue “Advances in Antiviral Agents against SARS-CoV-2 and Its Variants”
Francesca Esposito, Rolando Cannalire
Viruses (2023) Vol. 15, Iss. 9, pp. 1905-1905
Open Access
Francesca Esposito, Rolando Cannalire
Viruses (2023) Vol. 15, Iss. 9, pp. 1905-1905
Open Access
